News

H2020: Getting ideas to market
Enlarge image

FundingEU

H2020: Getting ideas to market

25.07.2014 - The European Commission aims to support innovation in Europe and announced a "Fast Track to Innovation" pilot as well as five innovation prices under Horizon 2020.

The European Commission is launching a new €100m "Fast Track to Innovation" (FTI) pilot action that will open for applications in early 2015. The measure belongs to the European Union's €80bn research and innovation programme Horizon 2020. It is the only such action that provides funding for projects that are close to market and business driven projects. The pilot is also open to proposals in any area of technology or  application. The grants are expected to help innovative businesses and organisations in the final push getting ideas to market. The FTI scheme will be open to applications from January 2015. It will support small consortia of three to five organisations with strong business participation and is open to any legal entity established in the EU or in a country associated to Horizon 2020.

In addition to the programme, the commission also announced five innovation prizes. The prizes offer a reward for technological breakthroughs of high societal relevance. Two of the prizes belong to the thematic area of "health", most notably the "Reduction of the Use of Antibiotics Prize". Worth €1m, the prize will reward a rapid test that can identify at the point of care patients with upper respiratory tract infections that can safely be managed without antibiotics. The contest will open in early 2015, and the prize will be awarded in late 2016.

"The response to the first Horizon 2020 calls has been enormous, with more than 17,000 proposals already submitted. I am impressed by the clear rise in industry interest, particularly from small businesses. Today we are firing the starting gun on the 2015 calls and I am confident they will meet equally strong demand. The Fast Track to Innovation and the new prizes will provide even more opportunities for innovators across Europe to get involved. With these measures we are contributing to increase Europe's competitiveness and create growth and jobs," commented Máire Geoghegan-Quinn, European Research, Innovation and Science Commissioner.

Watch a video on Horizon 2020

© european-biotechnology-news.com/um

ResearchUKEU

23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

M and AUKIreland

08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn). So far, Shire has rejected all offers from the US company.

M and ASwitzerland

04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/news/pos/2.html?cHash=807fa298e991d514ff878d4f7a870d11&sort=desc

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOINVENT INTERNATIONAL AB (S)3.10 SEK9.15%
  • Allergy Therapeutics (UK)19.12 GBP6.94%
  • PHARMING (NL)0.48 EUR6.67%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • CHRONTECH PHARMA (S)0.07 SEK-12.50%

TOP

  • WILEX (D)3.15 EUR331.5%
  • SANTHERA (CH)68.55 CHF99.3%
  • ADDEX (CH)4.08 CHF85.5%

FLOP

  • MERCK KGAA (D)65.43 EUR-48.6%
  • HYBRIGENICS (F)1.83 EUR-29.1%
  • PROSENSA (NL)9.48 USD-26.2%

TOP

  • SANTHERA (CH)68.55 CHF3489.0%
  • GW PHARMACEUTICALS (UK)427.00 GBP780.4%
  • PAION (D)2.79 EUR304.3%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-92.0%
  • PROSENSA (NL)9.48 USD-68.2%

No liability assumed, Date: 24.07.2014